{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:00:01Z","timestamp":1778626801517,"version":"3.51.4"},"reference-count":52,"publisher":"American Academy of Insurance Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Insur Med"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>\n                    There was a steady decrease in cardiovascular disease (CVD ischemic heart disease and stroke) mortality from 1960 to 2020, but since then, this decline has reversed. There have been over 228,000 excess CVD deaths through 2022,\n                    <jats:sup>1<\/jats:sup>\n                    undoubtedly partially due to the COVID-19 pandemic, but the mortality rate continues to rise (arguably due to the rising epidemic of obesity and diabetes). CVD remains the leading cause of death in developed countries, accounting for over 30% of deaths, and risk estimation is a cornerstone approach to guiding CVD prevention in clinical medicine. Data from the CDC reveal that 36% of US adults have no CVD risk factors, 35% have 1, and 29% have 2 or more risk factors. The age-adjusted percentage of adults with 2 or more CVD risk factors has increased between 2013-2014 to August 2021-August 2023, especially in older age groups.\n                    <jats:sup>2<\/jats:sup>\n                    Assessing the risk for CVD mortality is essential for the disability and life insurance industry required to assess that risk at a single point in time (at the issuance of an insurance policy). Evaluating this risk requires careful attention to modifiable and non-modifiable factors, including hypertension and other co-morbidities, abnormal lipid profiles, and lifestyle inequalities. The goal of this treatise is to evaluate the various CVD calculators, but also to review other risk factors that may not be routinely sought in estimating CVD risk. The importance of apolipoproteinB (apoB) and lipoprotein A (LpA) as better risk predictors than just elevated LDL levels will be emphasized, and evidence of systemic inflammation and insulin resistance will be proposed as essential early indicators of future cardiovascular disease.\n                  <\/jats:p>","DOI":"10.17849\/insm-53-1-1-8.2","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:51:37Z","timestamp":1770771097000},"page":"90-97","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating Cardiovascular Disease Risk"],"prefix":"10.17849","volume":"53","author":[{"given":"Rodney C.","family":"Richie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7324","reference":[{"key":"i-53-1-90-ref01","series-title":"Am J Prevent Med","first-page":"582","article-title":"Trends in Cardiovascular Disease Mortality Rates and Excess Deaths, 2010\u20132022","volume":"66","author":"Woodruff","year":"2024","unstructured":"Woodruff RC,\nTong X,\nKhan SS, et al. Trends in Cardiovascular Disease Mortality Rates and Excess Deaths, 2010\u20132022. Am J Prevent Med. 2024;66:582\u2013589. doi:10.1016\/j.amepre.2023.11.009. PMID: 37972797"},{"key":"i-53-1-90-ref02","series-title":"NCHS Data Brief","first-page":"10","article-title":"Prevalence of Cardiovascular Disease Risk Factors in Adults: United States, August 2021-August 2023","author":"Couch","year":"2025","unstructured":"Couch FA,\nMascarenhas R,\nStierman B,\nFryar CD. Prevalence of Cardiovascular Disease Risk Factors in Adults: United States, August 2021-August 2023. NCHS Data Brief. 2025:540:10. doi:10.15620\/cdc\/174623. PMID: 41027398"},{"key":"i-53-1-90-ref03","series-title":"Circulation","first-page":"1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","unstructured":"Wilson PW,\nD\u2019Agostino RB,\nLevy D,\nBelanger AM,\nSilbershatz H,\nKannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837\u20131847. doi:10.1161\/01.CIR.97.18.1837. PMID: 9603539"},{"key":"i-53-1-90-ref04","series-title":"Circulation","first-page":"3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).","year":"2002","unstructured":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 2002;106:3143\u20133421. PMID: 12485966"},{"key":"i-53-1-90-ref05","series-title":"Circulation","first-page":"743","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D\u2019Agotino","year":"2008","unstructured":"D\u2019Agotino RB Sr,\nVasan RS,\nPencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743\u2013753. doi:10.1161\/CIRCULATIONAHA.107.699579. PMID: 18212285"},{"issue":"suppl 2","key":"i-53-1-90-ref06","series-title":"Circulation","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","unstructured":"Goff DC Jr,\nLloyd-Jones DM,\nBennett G, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49\u2013S73 doi:10.1161\/01.cir.0000437741.48606.98. PMID: 24222018"},{"issue":"suppl 2","key":"i-53-1-90-ref07","series-title":"Circulation","first-page":"51","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce the atherosclerotic cardiovascular risk in adults: a report","volume":"129","author":"Stone","year":"2014","unstructured":"Stone NJ,\nRobinson JG,\nLichtenstein AH, et al.. American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce the atherosclerotic cardiovascular risk in adults: a report. Circulation. 2014;129(suppl 2):51\u2013545. doi:10.1161\/01.cir.0000437738.63853.7a"},{"key":"i-53-1-90-ref08","series-title":"Circulation","first-page":"e793","article-title":"Estimating longitudinal risks and benefits from cardiovascular preventive therapies among Medicare patients: the Million Hearts Longitudinal ASCVD Risk Assessment Tool: a special report from the American Heart Association and American College of Cardiology","volume":"135","author":"Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM,\nHuffman MD,\nKarmali KN, et al. Estimating longitudinal risks and benefits from cardiovascular preventive therapies among Medicare patients: the Million Hearts Longitudinal ASCVD Risk Assessment Tool: a special report from the American Heart Association and American College of Cardiology. Circulation. 2017;135:e793. doi:10.1161.CIR.0000000000000.467. PMID: 27815375"},{"key":"i-53-1-90-ref09","series-title":"Ann Intern Med","first-page":"266","article-title":"An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort","volume":"162","author":"DeFilippis","year":"2015","unstructured":"DeFilippis AP,\nYoung R,\nCarrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266\u2013275. doi:10.7326\/M14-1281. PMID: 25686167"},{"key":"i-53-1-90-ref10","series-title":"N Engl J Med","first-page":"874","article-title":"Hidden in plain sight\u2014reconsidering the use of race correction in clinical algorithms","volume":"383","author":"Vyas","year":"2020","unstructured":"Vyas DA,\nEisenstein LG,\nJones DS. Hidden in plain sight\u2014reconsidering the use of race correction in clinical algorithms. N Engl J Med. 2020;383:874\u2013882. doi:10.1056\/NEJMms2004740. PMID: 32853499"},{"key":"i-53-1-90-ref11","series-title":"J Am Soc Nephrol","first-page":"2987","article-title":"Removing race from kidney disease diagnosis","volume":"32","author":"Quaggin","year":"2021","unstructured":"Quaggin SE,\nPalevsky PM. Removing race from kidney disease diagnosis. J Am Soc Nephrol. 2021;32:2987\u20132989. doi:10.1681\/ASN.2021091284. PMID: 34753827"},{"key":"i-53-1-90-ref12","series-title":"Circulation","first-page":"1982","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","unstructured":"Khan SS,\nCoresh J,\nPencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023;148:1982\u20132004. doi:10.1161\/CIR.0000000000001191. PMID: 37947094"},{"key":"i-53-1-90-ref13","series-title":"Circulation","first-page":"430","article-title":"Development and validation of the American Heart Association\u2019s PREVENT Equations","volume":"149","author":"Khan","year":"2023","unstructured":"Khan SS,\nMatsushita K,\nSang Y, et al. Development and validation of the American Heart Association\u2019s PREVENT Equations. Circulation. 2023;149:430\u2013449. doi:10.1161\/CIRCULATIONAHA.123.067626. PMID: 37947085"},{"key":"i-53-1-90-ref14","series-title":"Circulation","first-page":"e1082","article-title":"2018 Guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","unstructured":"Grundy SM,\nStone NJ,\nBailey A, et al. 2018 Guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082\u2013e1143. doi:10.1161\/CIR.0000000000000625. PMID: 30586774"},{"key":"i-53-1-90-ref15","series-title":"Circulation","first-page":"2047","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction","volume":"118","author":"Langsted","year":"2008","unstructured":"Langsted A,\nFreiberg JJ,\nNordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation. 2008;118:2047\u20132056. doi:10.1161\/CIRCULATIONAHA.108.804146. PMID: 18955664"},{"key":"i-53-1-90-ref16","series-title":"JAMA","first-page":"989","article-title":"Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations","volume":"332","author":"Diao","year":"2024","unstructured":"Diao JA,\nShi I,\nMurthy VL,\nBuckley TA, et al. Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations. JAMA. 2024;332:989\u20131000. doi:10.1001\/jama.2024.12537. PMID: 39073797"},{"key":"i-53-1-90-ref17","series-title":"Pulmonology","first-page":"168","article-title":"COPD and Cardiovascular Disease","volume":"25","author":"Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 S,\nConde B,\nFragoso E,\nBol\u00e9o-Tom\u00e9 J,\nAreias V,\nCardoso J. COPD and Cardiovascular Disease. Pulmonology. 2019;25:168\u2013176. https:\/\/doi.org\/10.1016\/j.pulmoe.2018.09.006"},{"key":"i-53-1-90-ref18","series-title":"BMC Pulmonary Medicine","first-page":"73","article-title":"Causes of death in asthma, COPD and non-respiratory hospitalized patients: a multicentric study","volume":"13","author":"Soto-Campos","year":"2013","unstructured":"Soto-Campos JG,\nPlaza V,\nSoriano JB, et al. Causes of death in asthma, COPD and non-respiratory hospitalized patients: a multicentric study. BMC Pulmonary Medicine. 2013;13:73. https:\/\/doi.org\/10.1186\/1471-2466-13-73"},{"key":"i-53-1-90-ref19","series-title":"Front Cardiovasc Med","first-page":"861798","article-title":"Association between asthma and all-cause mortality and cardiovascular disease morbidity and mortality: a meta-analysis of cohort studies","volume":"9","author":"Zhang","year":"2022","unstructured":"Zhang B,\nLi Z-F,\nAn Z-Y, et al. Association between asthma and all-cause mortality and cardiovascular disease morbidity and mortality: a meta-analysis of cohort studies. Front Cardiovasc Med. 2022;9:861798. doi:10.3389\/fcvm.2022.861798. PMID: 35369308"},{"key":"i-53-1-90-ref20","series-title":"Nat Rev Cardiol","first-page":"399","article-title":"Apolipoprotein B-containing lipoproteins in atherogenesis","volume":"22","author":"Bor\u00e9n","year":"2025","unstructured":"Bor\u00e9n J,\nPackard CJ,\nBinder CJ. Apolipoprotein B-containing lipoproteins in atherogenesis. Nat Rev Cardiol. 2025;22:399\u2013413. doi:10.1038\/s41569-024-01111-0. PMID: 39743565"},{"key":"i-53-1-90-ref21","series-title":"JAMA","first-page":"754","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: updated evidence reports and systematic review for the US Preventive Services Task Force","volume":"328","author":"Chou","year":"2022","unstructured":"Chou R,\nCantor Ak,\nDana T, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence reports and systematic review for the US Preventive Services Task Force. JAMA. 2022;328:754\u2013771. doi:10.1001\/jama.2022.12138. PMID: 35997724"},{"key":"i-53-1-90-ref22","series-title":"Eur Heart J","first-page":"2478","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","author":"Madsen","year":"2017","unstructured":"Madsen CM,\nVarbo A,\nNordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017;38:2478\u20132486. doi:10.1093\/eurheartj\/ehx163. PMID: 28419274"},{"key":"i-53-1-90-ref23","series-title":"Molecules","first-page":"969","article-title":"Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment","volume":"28","author":"Lampsas","year":"2023","unstructured":"Lampsas S,\nXenou M,\nOikonomou E, et al. Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment. Molecules. 2023;28:969. doi:10.3390\/molecules28030969. PMID: 36770634"},{"key":"i-53-1-90-ref24","series-title":"Clin Chem","first-page":"1191","article-title":"Effect of weight loss on serum lipoprotein(a) concentrations in an obese population","volume":"37","author":"Coretti","year":"1991","unstructured":"Coretti JP,\nSterry JA,\nSparks JD, et al. Effect of weight loss on serum lipoprotein(a) concentrations in an obese population. Clin Chem. 1991;37:1191\u20131195. doi:10.1093\/clinchem\/37.7.1191. PMID: 1830250"},{"key":"i-53-1-90-ref25","series-title":"Circulation","first-page":"1135","article-title":"Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study","volume":"87","author":"Jenner","year":"1993","unstructured":"Jenner JL,\nOrdovas JM,\nLamon-Fava S,\nSchaefer MM, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation. 1993;87:1135\u20131141. doi:10.1161\/01.cir.87.4.1135. PMID: 8462142"},{"key":"i-53-1-90-ref26","series-title":"Circulation","first-page":"62","article-title":"Apolipoprotein B: Bridging the gap between evidence and clinical practice","volume":"150","author":"Oliveira-Gomes","year":"2024","unstructured":"Oliveira-Gomes DD,\nJoshi PH,\nPeterson ED,\nRohatgi A,\nKhera A,\nNavar AM. Apolipoprotein B: Bridging the gap between evidence and clinical practice. Circulation. 2024;150:62\u201379. doi:10.1161\/CIRCULATIONAHA.124.068885. PMID: 38950110"},{"key":"i-53-1-90-ref01","series-title":"Am J Prevent Med","first-page":"582","article-title":"Trends in Cardiovascular Disease Mortality Rates and Excess Deaths, 2010\u20132022","volume":"66","author":"Woodruff","year":"2024","unstructured":"Woodruff RC,\nTong X,\nKhan SS, et al. Trends in Cardiovascular Disease Mortality Rates and Excess Deaths, 2010\u20132022. Am J Prevent Med. 2024;66:582\u2013589. doi:10.1016\/j.amepre.2023.11.009. PMID: 37972797"},{"key":"i-53-1-90-ref02","series-title":"NCHS Data Brief","first-page":"10","article-title":"Prevalence of Cardiovascular Disease Risk Factors in Adults: United States, August 2021-August 2023","author":"Couch","year":"2025","unstructured":"Couch FA,\nMascarenhas R,\nStierman B,\nFryar CD. Prevalence of Cardiovascular Disease Risk Factors in Adults: United States, August 2021-August 2023. NCHS Data Brief. 2025:540:10. doi:10.15620\/cdc\/174623. PMID: 41027398"},{"key":"i-53-1-90-ref03","series-title":"Circulation","first-page":"1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","unstructured":"Wilson PW,\nD\u2019Agostino RB,\nLevy D,\nBelanger AM,\nSilbershatz H,\nKannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837\u20131847. doi:10.1161\/01.CIR.97.18.1837. PMID: 9603539"},{"key":"i-53-1-90-ref04","series-title":"Circulation","first-page":"3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).","year":"2002","unstructured":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 2002;106:3143\u20133421. PMID: 12485966"},{"key":"i-53-1-90-ref05","series-title":"Circulation","first-page":"743","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D\u2019Agotino","year":"2008","unstructured":"D\u2019Agotino RB Sr,\nVasan RS,\nPencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743\u2013753. doi:10.1161\/CIRCULATIONAHA.107.699579. PMID: 18212285"},{"issue":"suppl 2","key":"i-53-1-90-ref06","series-title":"Circulation","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","unstructured":"Goff DC Jr,\nLloyd-Jones DM,\nBennett G, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49\u2013S73 doi:10.1161\/01.cir.0000437741.48606.98. PMID: 24222018"},{"issue":"suppl 2","key":"i-53-1-90-ref07","series-title":"Circulation","first-page":"51","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce the atherosclerotic cardiovascular risk in adults: a report","volume":"129","author":"Stone","year":"2014","unstructured":"Stone NJ,\nRobinson JG,\nLichtenstein AH, et al.. American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce the atherosclerotic cardiovascular risk in adults: a report. Circulation. 2014;129(suppl 2):51\u2013545. doi:10.1161\/01.cir.0000437738.63853.7a"},{"key":"i-53-1-90-ref08","series-title":"Circulation","first-page":"e793","article-title":"Estimating longitudinal risks and benefits from cardiovascular preventive therapies among Medicare patients: the Million Hearts Longitudinal ASCVD Risk Assessment Tool: a special report from the American Heart Association and American College of Cardiology","volume":"135","author":"Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM,\nHuffman MD,\nKarmali KN, et al. Estimating longitudinal risks and benefits from cardiovascular preventive therapies among Medicare patients: the Million Hearts Longitudinal ASCVD Risk Assessment Tool: a special report from the American Heart Association and American College of Cardiology. Circulation. 2017;135:e793. doi:10.1161.CIR.0000000000000.467. PMID: 27815375"},{"key":"i-53-1-90-ref09","series-title":"Ann Intern Med","first-page":"266","article-title":"An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort","volume":"162","author":"DeFilippis","year":"2015","unstructured":"DeFilippis AP,\nYoung R,\nCarrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266\u2013275. doi:10.7326\/M14-1281. PMID: 25686167"},{"key":"i-53-1-90-ref10","series-title":"N Engl J Med","first-page":"874","article-title":"Hidden in plain sight\u2014reconsidering the use of race correction in clinical algorithms","volume":"383","author":"Vyas","year":"2020","unstructured":"Vyas DA,\nEisenstein LG,\nJones DS. Hidden in plain sight\u2014reconsidering the use of race correction in clinical algorithms. N Engl J Med. 2020;383:874\u2013882. doi:10.1056\/NEJMms2004740. PMID: 32853499"},{"key":"i-53-1-90-ref11","series-title":"J Am Soc Nephrol","first-page":"2987","article-title":"Removing race from kidney disease diagnosis","volume":"32","author":"Quaggin","year":"2021","unstructured":"Quaggin SE,\nPalevsky PM. Removing race from kidney disease diagnosis. J Am Soc Nephrol. 2021;32:2987\u20132989. doi:10.1681\/ASN.2021091284. PMID: 34753827"},{"key":"i-53-1-90-ref12","series-title":"Circulation","first-page":"1982","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","unstructured":"Khan SS,\nCoresh J,\nPencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023;148:1982\u20132004. doi:10.1161\/CIR.0000000000001191. PMID: 37947094"},{"key":"i-53-1-90-ref13","series-title":"Circulation","first-page":"430","article-title":"Development and validation of the American Heart Association\u2019s PREVENT Equations","volume":"149","author":"Khan","year":"2023","unstructured":"Khan SS,\nMatsushita K,\nSang Y, et al. Development and validation of the American Heart Association\u2019s PREVENT Equations. Circulation. 2023;149:430\u2013449. doi:10.1161\/CIRCULATIONAHA.123.067626. PMID: 37947085"},{"key":"i-53-1-90-ref14","series-title":"Circulation","first-page":"e1082","article-title":"2018 Guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","unstructured":"Grundy SM,\nStone NJ,\nBailey A, et al. 2018 Guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082\u2013e1143. doi:10.1161\/CIR.0000000000000625. PMID: 30586774"},{"key":"i-53-1-90-ref15","series-title":"Circulation","first-page":"2047","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction","volume":"118","author":"Langsted","year":"2008","unstructured":"Langsted A,\nFreiberg JJ,\nNordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation. 2008;118:2047\u20132056. doi:10.1161\/CIRCULATIONAHA.108.804146. PMID: 18955664"},{"key":"i-53-1-90-ref16","series-title":"JAMA","first-page":"989","article-title":"Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations","volume":"332","author":"Diao","year":"2024","unstructured":"Diao JA,\nShi I,\nMurthy VL,\nBuckley TA, et al. Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations. JAMA. 2024;332:989\u20131000. doi:10.1001\/jama.2024.12537. PMID: 39073797"},{"key":"i-53-1-90-ref17","series-title":"Pulmonology","first-page":"168","article-title":"COPD and Cardiovascular Disease","volume":"25","author":"Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 S,\nConde B,\nFragoso E,\nBol\u00e9o-Tom\u00e9 J,\nAreias V,\nCardoso J. COPD and Cardiovascular Disease. Pulmonology. 2019;25:168\u2013176. https:\/\/doi.org\/10.1016\/j.pulmoe.2018.09.006"},{"key":"i-53-1-90-ref18","series-title":"BMC Pulmonary Medicine","first-page":"73","article-title":"Causes of death in asthma, COPD and non-respiratory hospitalized patients: a multicentric study","volume":"13","author":"Soto-Campos","year":"2013","unstructured":"Soto-Campos JG,\nPlaza V,\nSoriano JB, et al. Causes of death in asthma, COPD and non-respiratory hospitalized patients: a multicentric study. BMC Pulmonary Medicine. 2013;13:73. https:\/\/doi.org\/10.1186\/1471-2466-13-73"},{"key":"i-53-1-90-ref19","series-title":"Front Cardiovasc Med","first-page":"861798","article-title":"Association between asthma and all-cause mortality and cardiovascular disease morbidity and mortality: a meta-analysis of cohort studies","volume":"9","author":"Zhang","year":"2022","unstructured":"Zhang B,\nLi Z-F,\nAn Z-Y, et al. Association between asthma and all-cause mortality and cardiovascular disease morbidity and mortality: a meta-analysis of cohort studies. Front Cardiovasc Med. 2022;9:861798. doi:10.3389\/fcvm.2022.861798. PMID: 35369308"},{"key":"i-53-1-90-ref20","series-title":"Nat Rev Cardiol","first-page":"399","article-title":"Apolipoprotein B-containing lipoproteins in atherogenesis","volume":"22","author":"Bor\u00e9n","year":"2025","unstructured":"Bor\u00e9n J,\nPackard CJ,\nBinder CJ. Apolipoprotein B-containing lipoproteins in atherogenesis. Nat Rev Cardiol. 2025;22:399\u2013413. doi:10.1038\/s41569-024-01111-0. PMID: 39743565"},{"key":"i-53-1-90-ref21","series-title":"JAMA","first-page":"754","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: updated evidence reports and systematic review for the US Preventive Services Task Force","volume":"328","author":"Chou","year":"2022","unstructured":"Chou R,\nCantor Ak,\nDana T, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence reports and systematic review for the US Preventive Services Task Force. JAMA. 2022;328:754\u2013771. doi:10.1001\/jama.2022.12138. PMID: 35997724"},{"key":"i-53-1-90-ref22","series-title":"Eur Heart J","first-page":"2478","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","author":"Madsen","year":"2017","unstructured":"Madsen CM,\nVarbo A,\nNordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017;38:2478\u20132486. doi:10.1093\/eurheartj\/ehx163. PMID: 28419274"},{"key":"i-53-1-90-ref23","series-title":"Molecules","first-page":"969","article-title":"Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment","volume":"28","author":"Lampsas","year":"2023","unstructured":"Lampsas S,\nXenou M,\nOikonomou E, et al. Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment. Molecules. 2023;28:969. doi:10.3390\/molecules28030969. PMID: 36770634"},{"key":"i-53-1-90-ref24","series-title":"Clin Chem","first-page":"1191","article-title":"Effect of weight loss on serum lipoprotein(a) concentrations in an obese population","volume":"37","author":"Coretti","year":"1991","unstructured":"Coretti JP,\nSterry JA,\nSparks JD, et al. Effect of weight loss on serum lipoprotein(a) concentrations in an obese population. Clin Chem. 1991;37:1191\u20131195. doi:10.1093\/clinchem\/37.7.1191. PMID: 1830250"},{"key":"i-53-1-90-ref25","series-title":"Circulation","first-page":"1135","article-title":"Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study","volume":"87","author":"Jenner","year":"1993","unstructured":"Jenner JL,\nOrdovas JM,\nLamon-Fava S,\nSchaefer MM, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation. 1993;87:1135\u20131141. doi:10.1161\/01.cir.87.4.1135. PMID: 8462142"},{"key":"i-53-1-90-ref26","series-title":"Circulation","first-page":"62","article-title":"Apolipoprotein B: Bridging the gap between evidence and clinical practice","volume":"150","author":"Oliveira-Gomes","year":"2024","unstructured":"Oliveira-Gomes DD,\nJoshi PH,\nPeterson ED,\nRohatgi A,\nKhera A,\nNavar AM. Apolipoprotein B: Bridging the gap between evidence and clinical practice. Circulation. 2024;150:62\u201379. doi:10.1161\/CIRCULATIONAHA.124.068885. PMID: 38950110"}],"container-title":["Journal of Insurance Medicine"],"original-title":[],"link":[{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/53\/1\/article-p90.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/53\/1\/article-p90.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/53\/1\/article-p90.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:46:55Z","timestamp":1771930015000},"score":1,"resource":{"primary":{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/53\/1\/article-p90.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":52,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.17849\/insm-53-1-1-8.2","relation":{},"ISSN":["0743-6661"],"issn-type":[{"value":"0743-6661","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}